PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced the completion of an expansion to its Rockford, IL facility to enhance its Specialty Drug Product Capabilities.
The 30,000+ sq. ft. dedicated to Specialty Drug Products now includes four high potent compound capable suites built to ISO8 standards. The suites are equipped with the latest in air-filtration technology – high-efficiency particle air (HEPA) filtration with 30 air turns per hour. PCI has also built three new secondary packaging areas to deliver increased scalability and installed three new coolers and a new freezer for -20°C to -8°C cold chain requirements.
“As we continue to see advancements in cancer and hormonal therapies, and growth in the allergen market, there is a stronger need in the marketplace for high potent compound suites,” said Angella Sutthiwan, Vice President and General Manager, PCI Pharma Services. “Our decision to expand this specialized service fuels our ability to support our growing client base and demonstrates why our clients continue to turn to PCI as the outsourcing partner they can trust for unmatched capacity and flexibility.”
This investment in Rockford comes on the heels of another expansion of the Rockford, IL facility in September to unveil a new state-of-the-art Clinical Center of Excellence.
“Across the globe, we are making strategic decisions that enable us to continue to support our clients’ business and meet increased demands for our integrated services,” said Salim Haffar, CEO, PCI Pharma Services. “At PCI, we are committed to helping our clients get life-changing therapies into the hands of those who need it most, anywhere in the world. Our latest investment in the Rockford site is further evidence of our dedication to stay out in front of our clients’ needs and offer them the best and most innovative solutions in the industry.”
About the Rockford, IL Facility
Rockford is the largest of PCI’s eight locations across the US, EU and Asia Pacific regions, providing industry-leading services for the clinical and commercial packaging of a diverse portfolio of products and specialized delivery forms destined to reach more than 100 countries across the world. The gated secured facility is classified by the Drug Enforcement Administration (DEA) as Schedule 3, features temperature and humidity control, an approved Foreign Trade Zone (FTZ) and offers TF1 and Uhlmann blistering, vibratory and slat filler bottling, powder filling, cartoning, carding, kitting and serialization capabilities. Warehouse storage includes freezer storage -15°C to -30°C and cold storage 2°C to 8°C.
About PCI Pharma Services
The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle – from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.
